Abstract: The invention relates to the novel use of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide, a pharmacologically tolerable salt thereof or its N-oxide in the treatment of multiple sclerosis.

Abstract: Method of thin layer preparation for a radionuclide source comprising the following steps: deposition of a drop of a radionuclide dissolved in a solvent onto a on a support substrate, placing said support substrate with said drop in a confined space with a reduced pressure, directing at least one flow of a hot gas onto the drop, rotating the source relative to the hot gas jet creating turbulences inside the drop, evaporating the solvent and obtaining a thin layer of dry radionuclide.

Abstract: A device that produces an electron beam with high optical quality for processing a sample, is presented. The optical quality is manifested by very high brightness and low energy spread. The device includes an electron source device comprising an electrode in the form of a shaped first layer, preferably in the form of a conducting crater carrying at least one nanotube, and an extracting electrode, which is formed with at least one aperture and is insulated from the firs layer. The source can be used in any column that requires such properties. The column according to the invention may be a full size or a miniature electron microscope, a lithography tool, a tool used for direct writing of wafers or a field emission display.

Abstract: The present invention relates to methods of controlling iron overload in a patient in need thereof. The present invention particularly relates to methods of treating hemochromatosis and other causes of iron overload.

Abstract: The present invention relates to pharmaceutical compositions, methods and kits that provide for the early diagnosis and treatment of lung cancer. More particularly, the present invention relates to pharmaceutical compositions containing uteroglobin for preventing or inhibiting metastasis of lung tumor cells and methods of using the same to prevent or inhibit metastasis of lung tumor cells. The present invention also relates to methods and kits for early diagnosis of metastatic lung cancer by assaying for uteroglobin and comparing the results against control cells. The present invention also relates to methods and kits for detection of metastatic lung cancer by assaying for the presence of an aberrant form of uteroglobin.

Abstract: A system and method for controlling an individual's body and temperature are provided. The system comprises a heat exchanger for transferring heat to or removing heat from portions of the individual's body surface, at least one BCT-sensing device for measuring the individual's actual BCT (aBCT) and emitting an aBCT data signal, at least one sensing device for measuring a parameter indicative of the heat transfer dynamics (HTD) between the body surface and the body's core, and emitting an HTD data signal, and a control module for receiving data signal from measuring devices, comprising the aBCT data signal and the HTD data signal, and for emitting a control signal for controlling heat exchange properties of the heat exchanger as a function of the data signals and a desired body core temperature (dBCT).

Abstract: The present invention relates to pharmaceutical compositions comprising and methods of using an N-linked urea or carbamate of a heterocyclic thioester for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance.

Abstract: Human herpes virus (HHV) 7 is capable of binding to the CD4 antigen and the HHV-7 or a binding protein derived therefrom is thus useful as a CD4-ligand for various therapeutic applications. HHV-6 or HHV-7 are lymphotropic and are thus useful as lymphotropic vectors for delivering DNA into lymphocytes.

Abstract: An intralesional method for treating a hypertrophic scar or keloid using a cryoprobe. The method comprises: (a) inserting the cryoprobe into the hypertrophic scar or keloid so that the cryoprobe is positioned within the hypertrophic scar or keloid; and (b) introducing a cryogen into the cryoprobe thereby freezing the hypertrophic scar or keloid. The cryoprobe has a sealed distal end comprising a cutting tip. Also disclosed is a cryoprobe comprising an elongated, uninsulated housing having a sealed distal end and a proximal end. The housing comprises therein a cryogen inlet tube. The cryoprobe further comprises a cutting tip at the distal end of the housing and a cryogen vent adjacent to the proximal end and in fluid communication with the interior of the housing.

Abstract: A heat exchanger for use in controlling subject's body temperature during a medical procedure comprises a flexible garment adapted for enveloping portions of the subject's body surface with dedicated sections for enveloping different body parts. Defined within the garment is a continuous, fluid tight space, wherein a flow path for heat-control fluid is defined between fluid inlet and fluid outlet. The inner faces of the garment's internal and external layers are made of a heat-weldable material and are point-welded to one another at a plurality of locations throughout the garment with a distance between two adjacent points being between about 8 to about 20 mm.

Abstract: Combinations of N-(3,5-dichloropyrid)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide, its pharmacologically tolerable salts or its N-oxide, with PDE3 inhibitors, and methods of use thereof, are disclosed for therapeutic purposes.

Abstract: A method and device for determining a thickness of a layer in an object. For each of a plurality of frequencies, a continuous vibrational wave is generated at a surface of the layer and an energy of a steady state echo wave produced in the object in response to the generated vibrational wave is measured. The thickness of the layer is then calculated based upon the measured energies of the steady state echoes.

Abstract: The present invention provides improved, low-cost fuel cells having reduced fuel crossover, reduced sensitivity to metal ion impurities and ability to operate under a broad range of temperatures. Additionally, new effective organic fuels are described for use in such fuel cells. The invention further provides improved methods for catalyst preparation and a new integrated flow field system for use in H2/O2 fuel cells.

Abstract: The invention relates to a method for the disposal of waste products containing hydrocarbons and/or halogenated waste products, wherein the waste products are made to react in a hydroxide molten bath in the absence of oxygen at temperatures of 400-900° C.

Abstract: The invention relates to a method for producing 1-methyl-3-nitroguanidine. According to said method, nitroguanidine is reacted with methylamine and/or a methylammonium salt in an aqueous solution, at temperatures of 30 to 60° C. and at a pH value of 95 to 12.3. In this way, yields of 1-methyl-3-nitroguanidine of at least 80% and degrees of purity>99% can be obtained in a particularly environmentally friendly and technically simple way.

Abstract: Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and Ar have the meanings indicated in the description, are novel active bronchial therapeutics.

Abstract: Compounds of formula (I) in which the substituents and symbols have the meanings indicated in the description, are suitable for the control of Helicobacter bacteria.

Abstract: Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6, R13 and R20 have the meaning indicated in the description, are novel active bronchial therapeutics

Abstract: The present invention provides a method of modulating the malignant properties of a cell in a human or other mammal by contacting a neoplastic cell with a growth modulating amount of an expressible nucleic acid sequence for ribonucleotide reductase R1 of the mammal. The present invention also provides and uses a growth modulating amount of the ribonucleotide reductase R1 protein or biologically active peptide to modulate the malignant properties of a cell in a human or other mammal. The method provides for a generally elevated expression of the R1 component of mammalian ribonucleotide reductase. The expressible nucleic acid sequence can be in the form of a vector for gene therapy.

Abstract: A system for recognizing the existence of and adjusting the psycho-acoustic parameters present in an audio digital CODEC. A audio digital CODEC is provided with various parameters that when changed affect the quality of the resultant audio. These psycho-acoustic parameters include the standard ISO parameters and additional parameters to aid in effecting a pure resulting audio quality. The psycho-acoustic parameters located in the audio digital CODEC can be monitored and controlled by the user. The parameters can be monitored by a speaker associated with the CODEC or headphones. The user can control the adjustment of the psycho-acoustic parameters through the use of knobs present on the front panel of the CODEC or graphic or digital representations. Adjustment of the parameters will provide real time change of the resulting audio sound that the user can monitor through the speaker or the headphones.